Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
---|---|---|---|---|---|
Melting Point | 203.0 | ℃ | >203 | ℃ | [MSDS] |
Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
---|---|---|---|---|---|---|
Absorption | 90.0 | % | 90 | % | PO, oral; | DRUGBANK |
Bioavailability | 23.0 | % | 23 | % | PO, oral; | DRUGBANK | Bioavailability | 5.0 | % | 5 | % | PO, oral; Raceme L; | DRUGBANK |
T Max | 1.3 | h | 1-1.5 | h | PO, oral; Raceme L; | DRUGBANK |
Clearance | 0.40 | L/h/kg | 0.4 | l/h/kg | intravenous injection, IV; | DRUGBANK | Clearance | 0.005000 | L/h/kg | 0.005 | l/h/kg | Renal clearance; | DRUGBANK | Clearance | 0.40 | L/h/kg | 6.67 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
Volume of Distribution | 2.7 | L/kg | 2.65 | L/kg | intravenous injection, IV; | DRUGBANK | Volume of Distribution | 2.7 | L/kg | 2.65 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
Half-life | 2.2 | h | ~2.2 | h | terminal half-life; | DRUGBANK | Half-life | 3.9 | h | 3.8-3.9 | h | different study; | DRUGBANK | Half-life | 6.0 | h | 5.96 | h | intravenous injection, IV; | DRUGBANK | Half-life | 5.7 | h | 5.69 | h | PO, oral; | DRUGBANK | Half-life | 8.0 | h | 8 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
Toxicity LD50 | 190.0 | mg/kg | 190.0 | mg/kg | PO, oral; mouse; | T3DB |
Eliminate Route | 90.0 | % | 90 | % | Urinary excretion; | DRUGBANK | Eliminate Route | 3.3 | % | 3.3 | % | Faeces excretion; | DRUGBANK |
Protein Binding | 13.5 | % | 12-15 | % | DRUGBANK | Protein Binding | 15.2 | % | 15.2±5.2 | % | Children; | DRUGBANK | Protein Binding | 16.2 | % | 16.2±1.1 | % | adults; | DRUGBANK |
Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
---|---|---|---|---|---|---|---|---|
Max dose for children | 20.0 | mg/day | 20 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for children | 30.0 | mg/day | 30 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for children | 50.0 | mg/day | 50 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for adolescents | 20.0 | mg/day | 20 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for adolescents | 30.0 | mg/day | 30 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for adolescents | 50.0 | mg/day | 50 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for adults | 20.0 | mg/day | 20 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for adults | 40.0 | mg/day | 40 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for geriatric | 20.0 | mg/day | 20 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |
Max dose for geriatric | 40.0 | mg/day | 40 | mg/day | PO, oral | Focalin XR | dexmethylphenidate hydrochloride | PDR |